Compare Nuwellis Inc (NUWE) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.6 (market cap $7.77B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is far larger — about 3531.8× Nuwellis Inc's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| NUWE | PDBC | |
|---|---|---|
Market Cap | $2.20M | $7.77B |
Volume | 121,544 | 4,055,996 |
Sector | Health | — |
52-Week High | $146.65 | $20.10 |
52-Week Low | $0.68 | $13.16 |
Typical Hold Time | 26 Days | 56 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
PDBC trades at $19.41, down 0.26% with neutral technical signals from moving averages and oscillators. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by new institutional positions from firms like Arlington Capital and Advisortrust Partners.
The commodity ETF faces a complex outlook with potential upside from ongoing geopolitical tensions and defensive portfolio rotation, but risks include the sharp increase in short interest and commodity market volatility. Analyst sentiment remains cautiously optimistic given the fund's strong 2026 performance and defensive characteristics in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
